ArticleInternational journal of molecular sciences2024
Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson's Disease.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy.Journal of neurology · 2025Observational
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions.Journal of translational medicine · 2025Review
- Neurofilament Light Chain from Neuronally Derived Extracellular Vesicles in Differentiating Parkinson's Disease from Essential Tremor with Resting Tremor.Molecular neurobiology · 2025Article
- Neuronally Derived Extracellular Vesicles' Oligomeric and p129-α-Synuclein Levels for Differentiation of Parkinson's Disease from Essential Tremor.International journal of molecular sciences · 2025Article
- Serum Tau Species in Progressive Supranuclear Palsy: A Pilot Study.Diagnostics (Basel, Switzerland) · 2024Article
- Erythrocytic α-Synuclein in Parkinson's Disease and Progressive Supranuclear Palsy-A Pilot Study.Biomedicines · 2024Article
- Proximity Elongation Assay and ELISA for the Identification of Serum Diagnostic Biomarkers in Parkinson's Disease and Progressive Supranuclear Palsy.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical differentiation of progressive supranuclear palsy (PSP) from Parkinson's disease (PD) is challenging due to overlapping phenotypes and the late onset of specific atypical signs. Therefore, easily assessable diagnostic biomarkers are highly needed. Since PD is a synucleopathy while PSP is a tauopathy, here, we investigated the clinical usefulness of serum oligomeric-α-synuclein (o-α-synuclein) and 181Thr-phosphorylated tau (p-tau181), which are considered as the most important pathological protein forms in distinguishing between these two parkinsonisms. We assessed serum o-α-synuclein and p-tau181 by ELISA and SIMOA, respectively, in 27 PSP patients, 43 PD patients, and 39 healthy controls (HC). Moreover, we evaluated the correlation between serum biomarkers and biological and clinical features of these subjects. We did not find any difference in serum concentrations of p-tau181 and o-α-synuclein nor in the o-α-synuclein/p-tau181 ratio between groups. However, we observed that serum p-tau181 positively correlated with age in HC and PD, while serum o-α-synuclein correlated positively with disease severity in PD and negatively with age in PSP. Finally, the o-α-synuclein/p-tau181 ratio showed a negative correlation with age in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.